Cargando…

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.

The effects of combretastatin A4 prodrug on perfusion and the levels of 31P metabolites in an implanted murine tumour were investigated for 3 h after drug treatment using nuclear magnetic resonance imaging (MRI) and spectroscopy (MRS). The area of regions of low signal intensity in spin-echo images...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beauregard, D. A., Thelwall, P. E., Chaplin, D. J., Hill, S. A., Adams, G. E., Brindle, K. M.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150333/ https://www.ncbi.nlm.nih.gov/pubmed/9667644

Ejemplares similares

Magnetic resonance imaging and spectroscopy of combretastatin A(4) prodrug-induced disruption of tumour perfusion and energetic status
Publicado: (1998)

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
por: Griggs, J, et al.
Publicado: (2001)

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
por: Grosios, K, et al.
Publicado: (1999)

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide
por: Parkins, C S, et al.
Publicado: (2000)

Early detection of tumour immune-rejection using magnetic resonance imaging
por: Hu, D-E, et al.
Publicado: (2003)

An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate
por: Williams, L J, et al.
Publicado: (2014)

Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy
por: Gu, Yongwei, et al.
Publicado: (2019)

Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study
por: Gaya, A, et al.
Publicado: (2008)

Folate Receptor-Mediated Enhanced and Specific Delivery of Far-Red Light-Activatable Prodrugs of Combretastatin A-4 to FR-Positive Tumor
por: Nkepang, Gregory, et al.
Publicado: (2014)

Cytotoxicity Studies of Novel Combretastatin and Pterostilbene Derivatives
por: Jakubowska, Joanna, et al.
Publicado: (2014)

Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents
por: Hura, Neha, et al.
Publicado: (2018)

Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
por: Kelly, Patrick M., et al.
Publicado: (2017)

Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse.
por: Trotter, M. J., et al.
Publicado: (1990)

The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate
por: Holmes, Toby, et al.
Publicado: (2020)

Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models
por: Reipsch, Franziska, et al.
Publicado: (2021)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
por: Rustin, G J, et al.
Publicado: (2010)

Synthesis and Cytotoxic Activity of a New Group of Heterocyclic Analogues of the Combretastatins
por: Lipeeva, Alla V., et al.
Publicado: (2014)

The effect of blood flow modification on intra- and extracellular pH measured by 31P magnetic resonance spectroscopy in murine tumours.
por: McCoy, C. L., et al.
Publicado: (1995)

The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate
por: Shepherd, Joanna, et al.
Publicado: (2017)

Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors
por: Kumar, Sunil, et al.
Publicado: (2013)

Combretastatin A4 disodium phosphate-induced myocardial injury
por: Tochinai, Ryota, et al.
Publicado: (2016)

Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications
por: Karatoprak, Gökçe Şeker, et al.
Publicado: (2020)

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells
por: Dey, Sanchareeka, et al.
Publicado: (2017)

Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis
por: Hori, K, et al.
Publicado: (2003)

A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
por: Hori, K, et al.
Publicado: (2002)

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.
por: Woods, J. A., et al.
Publicado: (1995)

The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4
por: Su, Min, et al.
Publicado: (2016)

Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours.
por: Chaplin, D. J., et al.
Publicado: (1995)

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate
por: Ibrahim, Mohamed A, et al.
Publicado: (2013)

Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101
por: Bao, Xin, et al.
Publicado: (2021)

A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
por: McKeage, Mark J, et al.
Publicado: (2011)

In vivo nuclear magnetic resonance spectroscopy of a transplanted brain tumour.
por: Koeze, T. H., et al.
Publicado: (1984)

Measuring the acute effect of insulin infusion on ATP turnover rate in human skeletal muscle using phosphorus-31 magnetic resonance saturation transfer spectroscopy
por: Lim, Ee Lin, et al.
Publicado: (2010)

In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification.
por: Bremner, J. C., et al.
Publicado: (1991)

Combretastatin A-4 efficiently inhibits angiogenesis and induces neuronal apoptosis in zebrafish
por: Shi, Yun-Wei, et al.
Publicado: (2016)

Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
por: Lian, Bo, et al.
Publicado: (2021)

Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity
por: Assali, Mohyeddin, et al.
Publicado: (2019)

Combretastatins D series and analogues: from isolation, synthetic challenges and biological activities
por: de Lima Neto, Jorge, et al.
Publicado: (2023)

Perfusion and spectroscopy magnetic resonance imaging in a case of lymphocytic vasculitis mimicking brain tumor
por: Muccio, Carmine Franco, et al.
Publicado: (2013)

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
por: Phillips, Roger M.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ot96jn44r9qm21i2rodr1385cj